No benefit from pazopanib in advanced kidney cancer after surgery to remove metastases
(ECOG-ACRIN Cancer Research Group) The results of the ECOG-ACRIN Cancer Research Group's phase three trial, E2810, show no disease-free survival benefit with the use of one year of pazopanib in patients with metastatic renal cell carcinoma (kidney cancer) who had no evidence of disease following surgery to remove further metastases. There was a trend toward decreased overall survival with pazopanib. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 3, 2019 Category: International Medicine & Public Health Source Type: news
Atezolizumab Plus Bevacizumab Might Help Some With Kidney Cancer Atezolizumab Plus Bevacizumab Might Help Some With Kidney Cancer
The anti-VEGF monoclonal antibody bevacizumab combined with the anti-PD-L1 antibody atezolizumab might beat sunitinib in some patients with previously untreated advanced renal-cell carcinoma (RCC), but uncertainty remains, according to a phase 3 trial.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - May 29, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news
Merck acquires Peloton Therapeutics for $1 billion
The acquisition of Peloton, which was seeking to go public last week, brings its lead kidney cancer drug candidate to Merck, strengthening its renal cell carcinoma presence (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - May 21, 2019 Category: Pharmaceuticals Source Type: news
Nivolumab with ipilimumab: Combination has added benefit in advanced renal cell carcinoma
(Institute for Quality and Efficiency in Health Care) There are advantages in overall survival, which are not offset by any disadvantages of similar importance. Extent of the added benefit depends on the patient risk scores. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 17, 2019 Category: International Medicine & Public Health Source Type: news
Avelumab & #43; Axitinib Approved for Treatment of Renal Cell Carcinoma
THURSDAY, May 16, 2019 -- Avelumab (BAVENCIO) was approved this week for first-line treatment of advanced renal cell carcinoma (RCC) in combination with axitinib, the U.S. Food and Drug Administration announced.
The agency based the approval on data... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 16, 2019 Category: Pharmaceuticals Source Type: news
FDA approves avelumab plus axitinib for renal cell carcinoma
On May 14, 2019, the Food and Drug Administration approved avelumab (BAVENCIO ®, EMD Serono, Inc.) in combination with axitinib for first-line treatment of patients with advanced renal cell carcinoma (RCC). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 16, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news
First-Line Therapy for Metastatic RCC Remains Controversial Amid New Approvals
The bar for the standard of care among patients with advanced renal cell carcinoma is set high as various promising combination therapies recently received FDA approval. (Source: CancerNetwork)
Source: CancerNetwork - May 16, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news
FDA Okays Another Immunotherapy Plus TKI for Advanced RCC FDA Okays Another Immunotherapy Plus TKI for Advanced RCC
The FDA has approved avelumab in combination with the tyrosine kinase inhibitor (TKI) axitinib for the first-line treatment of advanced renal cell carcinoma (RCC).FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 15, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Bavencio (Avelumab), Inlyta (Axitinib) Combination Approved for Advanced Renal Cell Carcinoma by FDA
Approval marks the first anti-PD-L1 therapy combination for RCC. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2019 Category: Cancer & Oncology Authors: Drew Boxler Source Type: news
FDA Approves Bavencio (avelumab) Plus Inlyta (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma
Darmstadt, Germany and New York, US, May 14, 2019– Merck KGaA, Darmstadt, Germany, which operates its biopharmaceutical business as EMD Serono in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 14, 2019 Category: Drugs & Pharmacology Source Type: news
Mutation Profiles May Aid in Treatment of Non –Clear-Cell Renal Cell Carcinoma
Analyzing somatic and germline mutations and MSI may reveal clinically actionable mutations in a proportion of patients with advanced RCC. (Source: CancerNetwork)
Source: CancerNetwork - May 8, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news
Heavier and taller children are more likely to develop kidney cancer as adults than their average-sized peers
(European Association for the Study of Obesity) A study of more than 300,000 individuals in Denmark, presented at this year's European Congress on Obesity in Glasgow, Scotland (April 28-May 1), reveals that heavier and taller children are at greater risk than their average-sized peers of developing the kidney cancer renal cell carcinoma (RCC) as adults. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 28, 2019 Category: International Medicine & Public Health Source Type: news
FDA Approves Pembrolizumab Plus Axitinib for Advanced RCC
TUESDAY, April 23, 2019 -- The combination of pembrolizumab and axitinib has been approved as a first-line treatment in advanced renal cell carcinoma (RCC), the U.S. Food and Drug Administration announced Friday.
The agency approved the drug... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 23, 2019 Category: Pharmaceuticals Source Type: news
FDA Approves Merck ’s Keytruda (pembrolizumab) in Combination With Inlyta (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC)
KENILWORTH, N.J.--(BUSINESS WIRE)--April 22, 2019 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 22, 2019 Category: Drugs & Pharmacology Source Type: news
Cabozanitinib Shows Anti-Tumor Activity Beyond Clear-Cell Renal Cell Carcinoma
A recent study inThe Lancet Oncology suggests that the benefits of one tyrosine kinase inhibitor may extend to other subtypes of RCC. (Source: CancerNetwork)
Source: CancerNetwork - April 4, 2019 Category: Cancer & Oncology Authors: John Schieszer Source Type: news
